Carsten Reinhardt, M.D. Ph.D.
(Managing Director, Chief Medical Officer)
Dr. Reinhardt joined immatics from Micromet, Inc., in October 2009, where, as Chief Medical Officer, he lead all cinical development and regulatory activities for the company. Before joining Micromet in 2005, Dr Reinhardt worked as International Medical Leader for Herceptin® at Hoffmann-La Roche (Basel, Switzerland) and as Head of Clinical Development at Fresenius Biotech (Munich, Germany), where he successfully developed later stage niche indication strategies leading to the approval of Removab® and label extensions of Herceptin®.
Prior to joining industry, Dr Reinhardt held medical positions and worked at various academic institutions (University of Tuebingen, Max Planck Institute, Munich) to complete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardt completed his Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany, and received a Medical Degree in 1994 from the University of Munich, Germany. He is a Visiting Professor for Pharmaceutical Medicine at the University of Basel.